$IMVT
Immunovant, Inc. Stock $imvt

$imvt Overview Financials Valuation SEC Filings Company Website

2022 Form 10-K Financial Statement

#000176401322000059 Filed on June 08, 2022

Income Statement

Concept	2022	2021 Q1	2021
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$54.23M	$10.30M	$39.51M
YoY Change	37.24%	62.97%	117.69%
% of Gross Profit
Research & Development	$101.8M	$18.62M	$68.60M
YoY Change	48.4%	31.4%	43.14%
% of Gross Profit
Depreciation & Amortization	$126.0K	$30.00K	$65.00K
YoY Change	93.85%		209.52%
% of Gross Profit
Operating Expenses	$156.0M	$28.92M	$108.1M
YoY Change	44.32%	41.21%	63.62%
Operating Profit
YoY Change
Interest Expense		$0.00	$0.00
YoY Change			-100.0%
% of Operating Profit
Other Income/Expense, Net	-$781.0K	$680.0K	$328.0K
YoY Change	-338.11%	-623.08%	-20.39%
Pretax Income	-$156.8M	-$28.24M	-$107.8M
YoY Change	45.48%	37.02%	62.6%
Income Tax	-$84.00K	-$80.00K	-$358.0K
% Of Pretax Income
Net Earnings	-$156.7M	-$28.16M	-$107.4M
YoY Change	45.89%	37.03%	61.82%
Net Earnings / Revenue
Basic Earnings Per Share	-$1.43		-$1.22
Diluted Earnings Per Share	-$1.43	-$288.0K	-$1.22
COMMON SHARES
Basic Shares Outstanding	109.7M shares	97.97M shares	87.76M shares
Diluted Shares Outstanding	109.7M shares		87.76M shares

Balance Sheet

Concept	2022	2021 Q1	2021
SHORT-TERM ASSETS
Cash & Short-Term Investments	$493.8M	$400.1M	$400.1M
YoY Change	23.42%	297.71%	297.71%
Cash & Equivalents		$400.1M
Short-Term Investments
Other Short-Term Assets	$6.253M	$8.300M	$8.300M
YoY Change	-24.66%	50.91%	50.91%
Inventory
Prepaid Expenses		$7.716M
Receivables	$12.23M	$596.0K
Other Receivables	$632.0K
Total Short-Term Assets	$512.9M	$409.0M	$409.0M
YoY Change	25.41%	274.97%	274.89%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.633M	$201.0K	$3.500M
YoY Change	-24.77%	209.23%	3400.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Long-Term Assets	$2.633M	$3.483M	$3.500M
YoY Change	-24.77%	1019.94%	1066.67%
TOTAL ASSETS
Total Short-Term Assets	$512.9M	$409.0M	$409.0M
Total Long-Term Assets	$2.633M	$3.483M	$3.500M
Total Assets	$515.6M	$412.5M	$412.5M
YoY Change	24.99%	277.09%	277.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$18.63M	$2.432M	$2.400M
YoY Change	676.21%	104.37%	100.0%
Accrued Expenses	$25.72M	$15.16M	$16.30M
YoY Change	57.79%	38.6%	49.54%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$44.52M	$18.77M	$18.80M
YoY Change	136.81%	22.54%	22.88%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.219M	$2.200M	$2.200M
YoY Change	-44.59%
Total Long-Term Liabilities	$1.219M	$2.200M	$2.200M
YoY Change	-44.59%
TOTAL LIABILITIES
Total Short-Term Liabilities	$44.52M	$18.77M	$18.80M
Total Long-Term Liabilities	$1.219M	$2.200M	$2.200M
Total Liabilities	$45.74M	$21.01M	$21.00M
YoY Change	117.8%	37.15%	37.25%
SHAREHOLDERS EQUITY
Retained Earnings		-$198.7M
YoY Change		117.76%
Common Stock		$10.00K
YoY Change		100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$469.8M	$391.5M	$391.5M
YoY Change
Total Liabilities & Shareholders Equity	$515.6M	$412.5M	$412.5M
YoY Change	24.99%	277.09%	277.06%

Cashflow Statement

Concept	2022	2021 Q1	2021
OPERATING ACTIVITIES
Net Income	-$156.7M	-$28.16M	-$107.4M
YoY Change	45.89%	37.03%	61.82%
Depreciation, Depletion And Amortization	$126.0K	$30.00K	$65.00K
YoY Change	93.85%		209.52%
Cash From Operating Activities	-$106.1M	-$22.50M	-$83.33M
YoY Change	27.34%	-2.39%	56.17%
INVESTING ACTIVITIES
Capital Expenditures	$254.0K	-$90.00K	$210.0K
YoY Change	20.95%	800.0%	577.42%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$254.0K	-$90.00K	-$210.0K
YoY Change	20.95%	800.0%	577.42%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$200.1M	760.0K	$383.1M
YoY Change	-47.76%	660.0%	160.67%
NET CHANGE
Cash From Operating Activities	-$106.1M	-22.50M	-$83.33M
Cash From Investing Activities	-$254.0K	-90.00K	-$210.0K
Cash From Financing Activities	$200.1M	760.0K	$383.1M
Net Change In Cash	$93.67M	-21.83M	$299.6M
YoY Change	-68.73%	-4.92%	220.11%
FREE CASH FLOW
Cash From Operating Activities	-$106.1M	-$22.50M	-$83.33M
Capital Expenditures	$254.0K	-$90.00K	$210.0K
Free Cash Flow	-$106.4M	-$22.41M	-$83.54M
YoY Change	27.33%	-2.73%	56.47%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001764013
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-38906
CY2022	dei	Entity Registrant Name EntityRegistrantName	IMMUNOVANT, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	83-2771572
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	320 West 37th Street
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10018
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	New York,
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2022	dei	City Area Code CityAreaCode	917
CY2022	dei	Local Phone Number LocalPhoneNumber	580-3099
CY2022	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
CY2022	dei	Trading Symbol TradingSymbol	IMVT
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2021Q3	dei	Entity Public Float EntityPublicFloat	347000000.0	USD
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	116505412	shares
CY2022	dei	Auditor Firm AuditorFirmId	42
CY2022	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2022	dei	Auditor Location AuditorLocation	Iselin, New Jersey
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	493817000	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	400146000	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12229000	USD
CY2021Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	596000	USD
CY2022Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	6253000	USD
CY2021Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	7716000	USD
CY2022Q1	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	632000	USD
CY2021Q1	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	548000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	512931000	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	409006000	USD
CY2021Q1	us-gaap	Assets Assets	412489000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15160000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1145000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2303000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3282000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	330000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	201000	USD
CY2022Q1	us-gaap	Assets Assets	515564000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	18629000	USD
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2432000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	24575000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1179000	USD
CY2022Q1	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	171000	USD
CY2021Q1	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	44520000	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	18771000	USD
CY2021Q1	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2021Q1	us-gaap	Common Stock No Par Value CommonStockNoParValue	0.0001
CY2022Q1	us-gaap	Common Stock No Par Value CommonStockNoParValue	0.0001
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	116482899	shares
CY2021Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	116482899	shares
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1219000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2238000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	45739000	USD
CY2021Q1	us-gaap	Liabilities Liabilities	21009000	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	97971243	shares
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	97971243	shares
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	12000	USD
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	10000	USD
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	824796000	USD
CY2021Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	590425000	USD
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	404000	USD
CY2021Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-298000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-355387000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-198657000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	469825000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	391480000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	515564000	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	412489000	USD
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	101808000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	68604000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-282000	USD
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	54225000	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	39513000	USD
CY2022	us-gaap	Operating Expenses OperatingExpenses	156033000	USD
CY2021	us-gaap	Operating Expenses OperatingExpenses	108117000	USD
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-781000	USD
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	328000	USD
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-156814000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-107789000	USD
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-84000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-358000	USD
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-156730000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-107431000	USD
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.43
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.43
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.22
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.22
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	109679256	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	109679256	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	87756513	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	87756513	shares
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-156730000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-107431000	USD
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	702000	USD
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-282000	USD
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	702000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-282000	USD
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-156028000	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-107713000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	94069000	USD
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	907000	USD
CY2021	imvt	Adjustments To Additional Paid In Capital Contribution Share Based Compensation AdjustmentsToAdditionalPaidInCapitalContributionShareBasedCompensation	184000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	18638000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-107431000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	391480000	USD
CY2022	imvt	Adjustments To Additional Paid In Capital Contribution Share Based Compensation AdjustmentsToAdditionalPaidInCapitalContributionShareBasedCompensation	1101000	USD
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	33143000	USD
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	702000	USD
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-156730000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	469825000	USD
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-156730000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-107431000	USD
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	34244000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	18822000	USD
CY2022	us-gaap	Depreciation Depreciation	126000	USD
CY2021	us-gaap	Depreciation Depreciation	65000	USD
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1106000	USD
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	933000	USD
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	282000	USD
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	11633000	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	596000	USD
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-2137000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-753000	USD
CY2022	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	85000	USD
CY2021	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	512000	USD
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	16254000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1251000	USD
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	9472000	USD
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	4468000	USD
CY2022	imvt	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-1179000	USD
CY2021	imvt	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-798000	USD
CY2022	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	176000	USD
CY2021	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	0	USD
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-106112000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-83327000	USD
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	254000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	210000	USD
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-254000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-210000	USD
CY2022	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	129000	USD
CY2021	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	1096000	USD
CY2022	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	0	USD
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	907000	USD
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1236000	USD
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	200129000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	383112000	USD
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-92000	USD
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	USD
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	93671000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	299575000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	400146000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	100571000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	493817000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	400146000	USD
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	127000	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	4215000	USD
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	166000	USD
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	493800000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-355400000	USD
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">[B] Use of Estimates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company regularly evaluates estimates and assumptions related to assets, liabilities, stock-based compensation, litigation accruals, clinical trial accruals, operating leases, research and development costs and income taxes. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company assessed the impact that the COVID-19 pandemic has had on its operations and financial results as of March 31, 2022 and through the issuance of this report. The Company’s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact the COVID-19 pandemic may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and expenses.</span></div>
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">[D] Concentration of Credit Risk</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentration of credit risk include cash. At March 31, 2022, the cash balance is kept in one banking institution that the Company believes is of high credit quality and is in excess of federally insured levels. The Company maintains its cash with an accredited financial institution and accordingly, such funds are subject to minimal credit risk. The Company has not experienced any losses on its cash.</span></div>
CY2022Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	USD
CY2021Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	USD
CY2022	us-gaap	Property Plant And Equipment Useful Life PropertyPlantAndEquipmentUsefulLife	P3Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10699595	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9094675	shares
CY2017Q4	imvt	Upfront Payments UpfrontPayments	30000000	USD
CY2017Q4	imvt	Percentage Of Research And Development Costs PercentageOfResearchAndDevelopmentCosts	0.50
CY2017Q4	imvt	Milestone Payments MilestonePayments	10000000.0	USD
CY2018Q4	imvt	Sub Licensed Agreement Aggregate Purchase Price SubLicensedAgreementAggregatePurchasePrice	37800000	USD
CY2022Q1	imvt	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	18196000	USD
CY2021Q1	imvt	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	10147000	USD
CY2022Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	679000	USD
CY2021Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1196000	USD
CY2022Q1	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	4456000	USD
CY2021Q1	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	3138000	USD
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1244000	USD
CY2021Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	679000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	24575000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15160000	USD
CY2022	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	1600000	USD
CY2021	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	1300000	USD
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-156814000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-107789000	USD
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-84000	USD
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-358000	USD
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-84000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-358000	USD
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-32931000	USD
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-22636000	USD
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	8978000	USD
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	6662000	USD
CY2022	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2021	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-363000	USD
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	2493000	USD
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1303000	USD
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	23283000	USD
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	15427000	USD
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	3121000	USD
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	1581000	USD
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	439000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	-439000	USD
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-481000	USD
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	713000	USD
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-84000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-358000	USD
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0005
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0033
CY2021	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-400000	USD
CY2022Q1	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	6726000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	6597000	USD
CY2022Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	40297000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	21865000	USD
CY2022Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5581000	USD
CY2022Q1	imvt	Deferred Tax Assets Leasing Arrangements DeferredTaxAssetsLeasingArrangements	501000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3623000	USD
CY2022Q1	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	6010000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	2790000	USD
CY2021Q1	imvt	Deferred Tax Assets Leasing Arrangements DeferredTaxAssetsLeasingArrangements	698000	USD
CY2022Q1	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	219000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	214000	USD
CY2022Q1	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	59334000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	35787000	USD
CY2022Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	58704000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	34953000	USD
CY2022Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	630000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	834000	USD
CY2022Q1	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	69000	USD
CY2021Q1	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	42000	USD
CY2022Q1	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	489000	USD
CY2020Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	11438290	shares
CY2020Q2	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	5719145	shares
CY2020Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	11.50
CY2021Q1	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	691000	USD
CY2022Q1	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	72000	USD
CY2021Q1	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	101000	USD
CY2022Q1	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	630000	USD
CY2021Q1	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	834000	USD
CY2022Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2021Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2022Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	58700000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	35000000	USD
CY2021Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q2	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	65800000	USD
CY2020Q2	imvt	Class Of Warrant Or Right Canceled ClassOfWarrantOrRightCanceled	61710	shares
CY2022	imvt	Business Combination Share Price Threshold Trading Days BusinessCombinationSharePriceThresholdTradingDays	20	tradingDay
CY2022	imvt	Business Combination Share Price Trading Period BusinessCombinationSharePriceTradingPeriod	30	tradingDay
CY2019Q3	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	1800000	shares
CY2019Q3	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	1800000	shares
CY2021Q1	imvt	Sale Of Stock Amount Maximum Offering Price SaleOfStockAmountMaximumOfferingPrice	900000000.0	USD
CY2021Q1	imvt	Sale Of Stock Percentage Of Proceeds Owed Through Sales Agreement SaleOfStockPercentageOfProceedsOwedThroughSalesAgreement	0.03
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	116482899	shares
CY2022Q1	us-gaap	Convertible Preferred Stock Shares Reserved For Future Issuance ConvertiblePreferredStockSharesReservedForFutureIssuance	10000	shares
CY2021Q1	us-gaap	Convertible Preferred Stock Shares Reserved For Future Issuance ConvertiblePreferredStockSharesReservedForFutureIssuance	10000	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8018731	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7988999	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	2188860	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1781043	shares
CY2022Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	13033788	shares
CY2021Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	10875718	shares
CY2021Q3	imvt	Share Based Compensation Arrangement By Share Based Payment Award Stock Options Repricing Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRepricingVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	8.62
CY2020Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3918849	shares
CY2021Q3	imvt	Share Based Compensation Arrangement By Share Based Payment Award Stock Options Repricing Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRepricingVestedAndExpectedToVestOutstandingNumber	2548636	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	2591110	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7988999	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	16.97
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y14D
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	25958000	USD
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2777249	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.15
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	22.97
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	156407	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	17.67
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8018731	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.48
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y6M7D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	60000	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3169990	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	9.06
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y8M12D
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	50000	USD
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.89
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	16.17
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	33143000	USD
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	18638000	USD
CY2020Q2	imvt	Number Of Sublease Agreements NumberOfSubleaseAgreements	2	subleaseAgreement
CY2022Q1	imvt	Lease Agreement Additional Renew Period LeaseAgreementAdditionalRenewPeriod	P2Y
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y
CY2021Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y
CY2021Q1	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.039
CY2022Q1	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.039
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	1200000	USD
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	1200000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1216000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1198000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	47000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2461000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	97000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2364000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1145000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1219000	USD

Files In Submission

Name	View Source	Status
0001764013-22-000059-index-headers.html	Edgar Link	pending
0001764013-22-000059-index.html	Edgar Link	pending
0001764013-22-000059.txt	Edgar Link	pending
0001764013-22-000059-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
imvt-20220331.htm	Edgar Link	pending
imvt-20220331.xsd	Edgar Link	pending
imvt-20220331xex231.htm	Edgar Link	pending
imvt-20220331xex311.htm	Edgar Link	pending
imvt-20220331xex312.htm	Edgar Link	pending
imvt-20220331xex321.htm	Edgar Link	pending
imvt-20220331xex322.htm	Edgar Link	pending
imvt-20220331xexhibit1016.htm	Edgar Link	pending
imvt-20220331xexhibit211.htm	Edgar Link	pending
imvt-20220331_cal.xml	Edgar Link	unprocessable
imvt-20220331_def.xml	Edgar Link	unprocessable
imvt-20220331_g1.jpg	Edgar Link	pending
imvt-20220331_g2.jpg	Edgar Link	pending
imvt-20220331_g3.jpg	Edgar Link	pending
imvt-20220331_g4.jpg	Edgar Link	pending
imvt-20220331_htm.xml	Edgar Link	completed
imvt-20220331_lab.xml	Edgar Link	unprocessable
imvt-20220331_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IMVT
Immunovant, Inc. Stock $imvt

2022 Form 10-K Financial Statement

#000176401322000059 Filed on June 08, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IMVT Immunovant, Inc. Stock $imvt

2022 Form 10-K Financial Statement

#000176401322000059 Filed on June 08, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IMVT
Immunovant, Inc. Stock $imvt